Chuaikaew Kokaew, Maneenil Gunlawadee, Thatrimontrichai Anucha, Dissaneevate Supaporn, Praditaukrit Manapat
Division of Neonatology, Department of Pediatrics, Faculty of Medicine, Prince of Songkla University, Songkhla 90110, Thailand.
J Clin Med. 2025 Jun 25;14(13):4502. doi: 10.3390/jcm14134502.
: Persistent pulmonary hypertension of the newborn (PPHN) is characterized by increased pulmonary vascular resistance, resulting in severe hypoxemia. This study determined the factors associated with increased risk of mortality and survival rate in infants with PPHN. : This retrospective study was conducted between 2010 and 2023. The risk factors for mortality were assessed by Cox's proportional hazard models, and the Kaplan-Meier survival curve was used to analyze the survival rates. : This study included 233 neonates with PPHN. Gestational age (GA) less than 28 weeks (adjusted hazard ratio [AHR] = 5.46, 95% confidence interval [CI]: 2.25-13.24, < 0.001), Small for gestational age (SGA) (AHR = 2.93, 95% confidence interval [CI]: 1.24-6.92, = 0.026), acute kidney injury (AKI) (AHR = 2.48, 95% CI: 1.27-4.84, = 0.01), pneumothorax (AHR = 3.03, 95% confidence interval [CI]: 1.48-6.21, = 0.003), vasoactive-inotropic score (VIS) at 24 h of age (AHR = 1.0026, 95% confidence interval [CI]: 1.0004-1.005, = 0.026), and score for neonatal acute physiology II (SNAP-II) ≥ 43 (AHR = 4.03, 95% CI: 1.66-9.77, = 0.005) were associated with an increased risk of mortality. The overall survival rate was 82.4%; it rose from 63.8% to 87.1% after inhaled nitric oxide (iNO) and extracorporeal membrane oxygenation (ECMO) were introduced ( < 0.001). The cumulative survival rates at the end of the 30 days were 62.1% (95% CI: 49.0-78.7) in the Pre-iNO era and 87.5% (95% CI: 82.7-92.6) in the Post-iNO/ECMO era, respectively ( < 0.001). : GA less than 28 weeks, SGA, AKI, pneumothorax, high VIS and SNAP-II scores were associated with mortality in infants with PPHN. The improvement in the survival rate was related to the provision of advanced care, including iNO and ECMO therapy.
新生儿持续性肺动脉高压(PPHN)的特征是肺血管阻力增加,导致严重低氧血症。本研究确定了与PPHN婴儿死亡风险增加和生存率相关的因素。 :本回顾性研究于2010年至2023年进行。通过Cox比例风险模型评估死亡风险因素,并使用Kaplan-Meier生存曲线分析生存率。 :本研究纳入了233例PPHN新生儿。胎龄(GA)小于28周(调整后风险比[AHR]=5.46,95%置信区间[CI]:2.25-13.24,<0.001)、小于胎龄儿(SGA)(AHR=2.93,95%置信区间[CI]:1.24-6.92,=0.026)、急性肾损伤(AKI)(AHR=2.48,95%CI:1.27-4.84,=0.01)、气胸(AHR=3.03,95%置信区间[CI]:1.48-6.21,=0.003)、出生24小时时的血管活性药物-正性肌力药物评分(VIS)(AHR=1.0026,95%置信区间[CI]:1.0004-1.005,=0.026)以及新生儿急性生理学II评分(SNAP-II)≥43(AHR=4.03,95%CI:1.66-9.77,=0.005)与死亡风险增加相关。总体生存率为82.4%;在引入吸入一氧化氮(iNO)和体外膜肺氧合(ECMO)后,生存率从63.8%升至87.1%(<0.001)。在iNO治疗前时代,30天结束时的累积生存率为62.1%(95%CI:49.0-78.7),在iNO/ECMO治疗后时代为87.5%(95%CI:82.7-92.6)(<0.001)。 :GA小于28周、SGA、AKI、气胸、高VIS和SNAP-II评分与PPHN婴儿的死亡相关。生存率的提高与提供包括iNO和ECMO治疗在内的高级护理有关。